Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Azathioprine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | HBB | P68871 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | GFER | P55789 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azathioprine SCHEMBL4436347 | 1.00 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL29693611 | 1.00 | MAPT (1.00) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL26152 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL317904 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL502599 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL3089846 | 0.99 | MAPT (0.98) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL4259183 | 0.92 | MAPT (0.84) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8354969 | 0.91 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL8511946 | 0.91 | MAPT (0.82) | MAPTHBBLMNATP53GMNN | |
| Azathioprine SCHEMBL2328735 | 0.91 | MAPT (0.82) | MAPTHBBLMNATP53GMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 126907 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144816-A1 | COMPOSITIONS AND METHODS FOR TREATING DEMENTIA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-4747263-A1 | LIPID NANOPARTICLES AND USES THEREOF | University of Connecticut (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4749286-A2 | METHOD OF ASSESSING RISK OF PML | Biogen MA Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075497-A | Use of NLRP3 agonist for tumor treatment | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075452-A | Application of phyllanthin in preparation of medicines for treating or preventing colonitis | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094692-A | Rezabrutinib for the treatment of itching associated with atopic dermatitis and/or prurigo nodularis | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260140113-A1 | PROTEIN BIOMARKERS FOR USE IN LUPUS NEPHRITIS | EXAGEN INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-0260428-A2 | Cationic surfactants and pharmaceutical compositions containing them | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-23 | — | — | EP | claimed |
| EP-0260429-A2 | N-alkylated quaternary nitrogen-containing heterocycles, process for their preparation and their use in pharmaceutical compositions | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-23 | — | — | EP | claimed |
| EP-0258672-A2 | Cationic surfactants and pharmaceutical compositions containing them | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-09 | — | — | EP | claimed |
| EP-0257400-A2 | Pharmaceutical compositions containing cationic surfactants | MEDICEChem.-Pharm. Fabrik Pütter GmbH & Co. KG (DE) | 1988-03-02 | — | — | EP | claimed |
| EP-0230574-A2 | Pharmaceutical compositions against infections caused by LAV/HTLV III virus and the use thereof | YALE UNIVERSITY (US) | 1987-08-05 | — | — | EP | claimed |
| EP-0081882-B1 | MEDICINE HAVING TRANSPLANT REJECTION AND/OR IMMUNOLOGICAL INFLAMMATION INHIBITING ACTIVITIES, AS WELL AS A METHOD FOR INHIBITING TRANSPLANT REJECTION AND/OR IMMUNOLOGICAL INFLAMMATION | Erasmus Universiteit Rotterdam (NL) | 1986-04-16 | — | — | EP | claimed |
| EP-0126684-A2 | Drug delivery system utilizing thermosetting gels | MERCK & CO. INC. (US) | 1984-11-28 | — | — | EP | claimed |
| US-4474751-A | SUSTAINED RELEASE USING AN ALKYLENEDIAMINE-MODIFIED ETHYLENE OXIDE-PROPYLENE OXIDE COPOLYMER | MERCK & CO., INC. (US) | 1984-10-02 | — | — | US | claimed |
| US-4452794-A | MIXTURE OF A PROSTAGLANDIN DERIVATIVE AND A CORTICOSTEROID OR A MERCAPTOPURINE | ERASMUS UNIVERSITEIT ROTTERDAM (NL) | 1984-06-05 | — | — | US | claimed |
| EP-0081882-A1 | Medicine having transplant rejection and/or immunological inflammation inhibiting activities, as well as a method for inhibiting transplant rejection and/or immunological inflammation | Erasmus Universiteit Rotterdam (NL) | 1983-06-22 | — | — | EP | claimed |